BEDFORD, Mass. - Lantheus Holdings, Inc. (NASDAQ: LNTH), a leader in the radiopharmaceutical industry, announced today the completion of its acquisition of Evergreen Theragnostics, Inc., a ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to ...

Lantheus (LNTH) Holdings announced that it has completed its previously announced acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The acquisition was first ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus” or the "Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling ...

Explore the detailed Lantheus Holdings Inc balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...

Ferrovial SA is engaged in maintenance and upkeep of infrastructure, facilities and buildings; waste collection and treatment. The Company's segments are Construction, Services, Toll roads, and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million.

CytoSite will lead initial clinical development with Lantheus having an exclusive option to acquire worldwide development and commercialization rights to the radiotracer. BOSTON, March 26 ...